Background: Cervical Cancer is among the most commonly diagnosed cancers in women worldwide. It is 4th most common cancer in women worldwide. HPV (Human Papilloma Virus) infection is the major risk factor for Cervical Cancer. Treatment of Early-stage Cervical Cancer - Stage IA₁, IA₂ → Surgery or ICRT Alone. Stage IB₁ → Surgery or EBRT + ICRT. Stage IB₂ / IIA → Surgery + Post op RT. Advanced stage Cervical Cancer - Stage IIB, III, IV → Conc. Chemoradiotherapy.

Objective: This study seeks a) To evaluate efficacy & toxicity of a concomitant weekly brachytherapy regimen of Carcinoma Cervix b) To compare locoregional response in two arms; two months after completion of treatment & at the end of six months of radiotherapy.

Materials & Methods: Forty-five patients of Ca. Cervix were enrolled who have not undergone surgery. They were randomized in two arms. Arm A received Radiotherapy 46 Gy / 23 # + Conc. Inj. Cisplatin weekly followed by HDR ICRT 7 Gy/fraction twice weekly for total 3 fractions. Arm B received Radiotherapy 46 Gy / 23 # + Conc. Inj. Cisplatin weekly along with Concomitant weekly HDR ICRT 7 Gy/fraction for total 3 fractions.

Results: 81.81% (18) in Arm A & 83.33% (15) in Arm B had complete response -18.18% patients (4) in Arm A & 16.67% (3) in Arm B had Partial Response - 2 months after Treatment Completion

Conclusion: Concomitant HDR ICRT Brachytherapy sessions along with EBRT & Conc. Cisplatin administration resulted in better Complete Response Rates, toxicity profile, shortened overall Treatment time, decreased hospital stay & can be considered as a reasonable alternative to sequential HDR ICRT.

Keywords: Bilateral Salpingo-oophorectomy, External Beam Radiotherapy, High Dose Rate, Intra Cavitary Radiotherapy, Overall Treatment time, Complete Response, Partial Response

1. International Journal of women`s health. 2015; 7:405-414. Published online 2015 Apr 16. Aswathy Sreedevi, Reshma Javed, and Avani Dinesh. PMCID:
2. Cervical cancer treatment; National Cancer Institute at the National Institutes of health, U.S. Department of Health and Human Services: June 12,
3. NCCN Guidelines version 2.2015 (and 1.2017 updates): Cervical cancer; NCCN Framework: Enhanced
4. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Subir Nag, M.D., Beth Erickson, M.D., Bruce Thomadsen, M.D., Colin Orton, Ph.D., Jeffrey D Demanes, M.D., Daniel Petereit, M.D., American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):201-11.
5. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence— the University of Wisconsin experience. Daniel G. Petereit, M.D.1, Jann N. Sarkaria, M.D.2, David M. Potter, Ph.D.3, Julian C. Schink, M.D. Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1267-74.
6. High dose rate brachytherapy for carcinoma of the uterine cervix: comparison of two different fractionation regimens.Le Pechoux C1, Akine Y, Sumi M, Tokuuye K, Ikeda H, Yajima M, Yamada T, Tanemura K, Tsunematsu R, Ohmi K, et al. Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):735-41.
7. Carcinoma of the uterine cervix: twice- versus once-weekly high-dose-rate brachytherapy.Hama Y1, Uematsu M, Nagata I, Shioda A, Suda A, Sakurai Y, Kono M, Tamura T, Kusano S. 2001 Apr;219(1):207-12
8. Combination external beam radiotherapy and high-dose- rate intracavitary brachytherapy for uterine cervical cancer: Analysis of dose and fractionation schedule. kafumi Toita, M.D., Yasumasa Kakinohana, Ph.D., Kazuhiko Ogawa, M.D., Genki Adachi, M.D., Hidehiko Moromizato, M.D., Yutaka Nagai, M.D., Toshiyuki Maehama, M.D., Kaoru Sakumoto, M.D., Koji Kanazawa, M.D., Sadayuki Murayama, M.D. Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1344-53.
9. Effects of Treatment Duration During Concomitant Chemoradiation Therapy for Cervical Cancer. Narek Shaverdian, Vinai Gondi, MD, Kathryn L. Sklenar, Emily F. Dunn, MD, Daniel G. Petereit, MD, Margaret R. Straub, PA- C, Kristin A. Bradley, MD. Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):562-8. doi: 10.1016/j.ijrobp.2013.01.037. Epub 2013 Apr
10. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.Chen SW1, Liang JA, Yang SN, Ko HL, Lin FJ. Radiother Oncol. 2003 Apr;67(1):69-76.
11. "Long-term follow-up of potentiation of radiotherapy by cis- platinum in advanced cervical cancer." (Wong LC, Gynecol Oncol. 1989 Nov;35(2):159-63.).
12. Efficacy of Concomitant Cisplatin Plus Radiotherapy and High Dose Rate Brachytherapy versus Radiotherapy Alone. For Stage IIIB Epidermoid Cervical Cancer: A Ten-Year Randomized Controlled Trial. A.C. Zuliani, L.O. Sarian,
13. C. Esteves, G.A. Souza, M.O. Cunha, J.C. Teixeria, L.C. Teixeira. Campinas University, Brazil. J Clin Oncol. 2014 Feb 20;32(6):542-7. doi: 10.1200/JCO.2013.50.1205. Epub 2014 Jan 21.
14. Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis." Wang N, Arch et al. Arch Gynecol Obstet. 2011 Jan;283(1):103-8. doi: 10.1007/s00404-010-1385-5. Epub 2010 Feb

Poonam Gautam

Junior Resident, Department of Radiation Oncology, J.K. Cancer Institute, G.S.V.M. Medical College, Kanpur, Uttar Pradesh, India